InvestorsObserver
×
News Home

LAVA Therapeutics N.V. Up 1.04% To $4.85 After Earnings Beat

Thursday, November 17, 2022 11:10 AM | InvestorsObserver Analysts

Mentioned in this article

LAVA Therapeutics N.V. Up 1.04% To $4.85 After Earnings Beat

LAVA Therapeutics N.V. (LVTX) said after close Wednesday that it earned $0.04 per share in quarter three 2022.

On the revenue line, the company reported $15.3 million, beating estimates by $4.7 million.

In the same quarter a year ago, the company lost $0.27 per share on revenue of $2.1 million.

The stock is up 1.04% to $4.85 after the report.

Despite revenues increasing, earnings decreased, signaling a decline in profit margins.

Wall Street Analysts had an average rating of Strong Buy on the stock prior to the report.

Trading in the five days leading up to the report earned LAVA Therapeutics N.V. a Bearish Sentiment Rank from InvestorsObserver.

Prior to the report, InvestorsObserver gave the stock an overall score of 79. Meanwhile, the average Wall Street analyst rated the stock a Strong Buy.

LAVA Therapeutics NV is a biotechnology company. It is focused on transforming cancer treatment by developing a platform of novel bispecific antibodies designed to selectively induce gamma-delta T cell-mediated immunity against tumor cells.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App